A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (NCT04188548)
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
🩺 Plain-English Summary (8th-Grade Level)
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (74 Sites)
Showing the first 25 of 74 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- Beverly Hills Cancer Center — Beverly Hills, California
- University of California, Irvine — Orange, California
- UCSF Medical Center at Mission Bay — San Francisco, California
- Mayo Clinic in Florida — Jacksonville, Florida
- Lake Nona DDU — Orlando, Florida
- Winship Cancer Center Emory University — Atlanta, Georgia
- Community Cancer Center North — Indianapolis, Indiana
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Minnesota Oncology/Hematology PA — Minneapolis, Minnesota
- Mayo Clinic — Rochester, Minnesota
- Washington University — St Louis, Missouri
- Memorial Sloan Kettering - Bergen — Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center — Commack, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Wilmot Cancer Institute — Rochester, New York
- Duke University — Durham, North Carolina
- Ohio State University Medical Center — Columbus, Ohio
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center — Oklahoma City, Oklahoma
- Asante Rogue Regional Medical Center — Medford, Oregon
- UPMC Hillman Cancer Center Harrisburg — Harrisburg, Pennsylvania
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.